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Mastitomics, the integrated omics of bovine milk
in an experimental model of Streptococcus uberis
mastitis: 1. High abundance proteins, acute phase
proteins and peptidomics†
Funmilola Clara Thomas,a William Mullen,b Riccardo Tassi,c Adela Ramı´rez-Torres,d
Manikhandan Mudaliar,ae Tom N. McNeilly,c Ruth N. Zadoks,ac Richard Burchmoree
and P. David Eckersall*a
A peptidomic investigation of milk from an experimental model of Streptococcus uberis mastitis in dairy
cows has incorporated a study of milk high abundance and acute phase (APP) proteins as well as
analysis of low molecular weight peptide biomarkers. Intramammary infection (IMI) with S. uberis caused
a shift in abundance from caseins, b-lactoglobulin and a-lactalbumin to albumin, lactoferrin and IgG
with the increase in lactoferrin occurring last. The APP response of haptoglobin, mammary associated
serum amyloid A3 and C-reactive protein occurred between 30–48 hours post challenge with peak
concentrations of APPs at 72–96 hours post challenge and declined thereafter at a rate resembling the
fall in bacterial count rather than the somatic cell count. A peptide biomarker panel for IMI based on
capillary electrophoresis and mass spectrometry was developed. It comprised 77 identified peptides
(IMI77) composed mainly of casein derived peptides but also including peptides of glycosylation depen-
dent cell adhesion molecule and serum amyloid A. The panel had a biomarker classification score that
increased from 36 hour to 81 hour post challenge, significantly differentiating infected from non-
infected milk, thus suggesting potential as a peptide biomarker panel of bovine mastitis and specifically
that of S. uberis origin. The use of omic technology has shown a multifactorial cross system reaction in
high and low abundance proteins and their peptide derivatives with changes of over a thousand fold in
analyte levels in response to S. uberis infection.
1. Introduction
Mastitis, mostly caused by bacterial infection of the mammary
gland, is the major infectious disease problem in dairy cows,
being estimated to cost the global dairy industry h16–26 billion
per annum based on a global dairy cow population of 271 million
dairy cows (www.dairy.ahdb.org.uk, accessed March 2016) and
a cost to farmers of h61–97 per animal.1 The early detection of
intra-mammary infections (IMI), the main cause of mastitis,
would be greatly beneficial in allowing early treatment and
prevention of onward transmission of disease. Furthermore
early characterisation of the bacterial species causing mastitis
would allow more targeted chemotherapy, which may help to
reduce inappropriate use of antibiotics.2 The last decade has
shown a major increase in the use of omics technologies in
experimental biology and human disease investigations, but,
with the exception of genomics, the application of advanced
analytical technologies such as proteomics and metabolomics
has been limited in studies of animal health and disease. This
is undergoing change.3 This paper is the first of a series of three
in which protein and metabolite alteration in the composition
of milk during bovine mastitis was investigated with the aim of
characterising the molecular biosystem of milk to increase our
understanding of the pathology of the disease and to identify
potential biomarkers for early detection of IMI.
In this series of studies, changes in milk during mastitis
were investigated utilising an established experimental model
of the disease4 induced by Streptococcus uberis (S. uberis) which
is one of the most prevalent causes of bovine mastitis in the
United Kingdom5–7 and other countries.6–9 In the first paper,
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we focus on high abundance proteins, acute phase proteins10
and quantitative peptidomics.11 In the subsequent paper, a
label free quantitative proteomic method will be used to
monitor changes in higher Mw proteins of milk,
12 and in the
final paper of the series, the alteration of low Mw metabolites
will be described.13 All investigations used milk samples from
an experimental model of S. uberis mastitis used for the inves-
tigation of host immune responses in milk.4 This has previously
revealed changes in concentrations of cytokines such as TNFa
and interleukins 1-b and 6, which are associated with induction
of the acute phase response,14–16 as well as recruitment of
lymphocytes (CD4, CD8 and gd T cells) and polymorphonuclear
cells into the milk.4
The high abundance proteins in healthy milk consist largely of
the caseins, b-lactoglobin and a-lactoglobin17 and reduction in these
major proteins in milk due to IMI have been documented,18,19 as
well as increases in albumin, lactoferrin and immunoglobulins.20,21
However there has been little investigation of the time course of
changes in these high abundance proteins particularly in relation to
changes in the low abundance proteins such as acute phase
proteins (APP) in milk.
Acute phase proteins are serum proteins which increase
(or decrease) in concentration by over 25% following stimula-
tion by pro-inflammatory cytokines such as TNFa and IL6, and
APP are now recognised as also being elevated in milk during
mastitis.22 Haptoglobin (Hp) and mammary associated serum
amyloid A3 (MSAA3), the isoform of SAA synthesised and
secreted by the mammary epithelial cells are recognised as
milk APP. For example, Pedersen and others23 studied the early
inflammatory responses of the host to an experimental S. uberis
infection and showed that infection causes a rise in milk Hp
and MSAA3. Previous studies in an experimental model of
Staphylococcus aureus (S. aureus) induced mastitis have also
demonstrated that measuring APP could be useful in identification
of the inflammatory response to the mammary infections.10
Although several recent studies on APP in milk during mastitis
have focussed on Hp and SAA, some investigations have identified
a possible value of bovine milk C-reactive protein (CRP) as a
biomarker of bovine mastitis.24–27 However, variation of CRP
during the course of an experimental infection has not been
previously reported. In addition, APP profiles have been described
during the onset of infection, but seldom during resolution of IMI.
Knowledge of the change in concentration during resolution of
infection is crucial for assessment of the diagnostic specificity of
APP as an indicator of IMI.
While there have been several proteomic investigations of
milk during mastitis20,28–30 the lower Mw peptides of milk have
had less investigation. Our earlier study of the peptidome
of milk during clinical mastitis, caused by S. aureus and
Escherichia coli, indicated that analyses using a peptide bio-
marker panel could have potential in diagnosis of the disease11
but the milk peptidome has not been monitored for changes
over the course of an experimental infection. Biomarker dis-
covery using a combination of capillary electrophoresis and
mass spectroscopy (CE-MS) has enabled the identification of
peptide panels which are used in diagnostic procedures for
human diseases31 and have the ability to be applied to diseases
of livestock.32
Therefore the aim of this study is to identify the eﬀects of
S. uberis mastitis on the molecular pathophysiology of (a) high
abundance milk proteins, (b) the APP in the low abundance
milk proteins and (c) low Mw peptides (o25 kD) in milk during
IMI. The research described here is the first of three linked
mastitomic studies11,12 which along with clinical and immuno-
logical data of the same sample sets4 aims to contribute to an
integrated systems biology approach to increase our under-
standing of bovine mastitis.
2. Methods
2.1 Experimental challenge model of S. uberis mastitis
Milk samples were obtained from an intramammary challenge
study of a single udder quarter from each of six healthy Holstein
cows using a putative host adapted strain of S. uberis, strain FSL
Z1-048. Full details of the procedure and the results of clinical
evaluation of infected cows as well as laboratory investigation of
these milk samples such as for microbiology, somatic cell count
(SCC), cytokines and lymphocyte ratios have been previously
reported.4 The milk samples were stored at 20 1C in the period
between the analyses reported in Tassi et al.4 and the investiga-
tion described here. Samples were obtained at 19 time points
from each challenged quarter comprising 0, 6, 12, 18, 24, 30, 36,
42, 48, 57, 72, 81, 96, 120, 144, 168, 192, 240 and 312 hours (h)
post challenge (PC) and at 7 time points including 0, 12, 36, 57,
96, 192 and 312 h PC, from the control quarters (n = 1 per cow)
that were infused with 2 ml sterile phosphate buﬀered saline
(PBS). The timings were designed for collection at every 6 hours
for the first 2 days; from 2 to 11 d PC, milk samples were collected
twice a day; and from 11 to 13 d PC once a day. Skimmed milk
was prepared by centrifuging 50 ml of milk at 2800 g at 4 1C for
20 minutes (min). The fat layer was discarded and the super-
natant was transferred to a new 50 ml Falcon tube. Centrifuga-
tion was repeated and the supernatant was stored at 20 1C. All
animal experiments were conducted at the Moredun Research
Institute (Penicuik, UK) with approval of the Institute’s Experi-
ments and Ethical Review Committee in accordance with the
Animals (Scientific Procedures) Act 1986.4
2.2 High abundance milk proteins: one dimensional
electrophoresis
Prior to gel electrophoresis, protein concentration was deter-
mined using the Bradford protein assay with bovine serum
albumin as standard (BSA; Sigma-Aldrich, USA). Sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was
performed on 4–15% gradient polyacrylamide gels in a Criterion
electrophoresis system (BioRad Ltd, Hemel Hempstead, UK) as
previously described.33 Samples of milk taken at each time point
were separated by SDS-PAGE. The identity of protein in the SDS-
PAGE bands was determined in a reference gel by analysis of
milk from a healthy cow and a cow with mastitis run under the
identical conditions, followed by LC-MS/MS. Protein bands were
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excised and processed33 prior to analysis at Glasgow Polyomics
on a nanoflow uHPLC system (Thermo RSLCnano) and electro-
spray ionisation (ESI) mass spectrometry (MS) on an Amazon
ion trap MS/MS (Bruker Daltonics). MS data were processed
using Data Analysis software (Bruker) and the automated
Matrix Science Mascot Daemon server (v2.1.06). Protein identi-
fications were assigned using the Mascot search engine to
interrogate protein sequences in the NCBI databases restricting
the search to Bos taurus proteins.
2.3 Acute phase protein assays
Milk samples from all 19 time points (for challenged quarters;
7 time points for control quarters) were assayed for bovine Hp,
MSAA3 and CRP. An in-house ELISA for bovine Hp using
purified polyclonal rabbit anti-bovine Hp IgG (Life Diagnostics
Inc, West Chester, Pennsylvania, USA) was carried out as described
previously.27 Commercial ELISAs for SAA (Tridelta Development
Ltd, Dublin Ireland) and bovine CRP (Life Diagnostics Inc, West
Chester, Pennsylvania, USA) were used to quantify these proteins
in milk from the S. uberis experimental model of mastitis as
described previously.27
2.4 Peptidome analysis: sample preparation, CE-MS setup
and data processing
Samples were prepared and run on capillary electrophoresis-
mass spectrometry (CE-MS) with modifications to the methods
described previously.11 Briefly, 0.1% PMSF was added to each
milk sample. Aliquots of 150 ml were diluted with the same
volume of 2 M urea, 100 mM NaCl, 10 mM NH4OH and 0.02%
SDS. High Mw molecules were filtered with a cut-oﬀ 420 kDa
Centrisart ultrafiltration tube (Sartorius, Germany) for 1 h,
3400 rpm, 4 1C. To discard urea and electrolytes, a NAP-5
column (GE Healthcare, Sweden) was used, equilibrated as
recommended by the manufacturer. To elute the peptides from
the column, 700 ml of the NH4OH were used. Protein concen-
tration was determined by a bicinchoninic acid (BCA) assay,
using BSA as standard. Aliquots were restored to a final concen-
tration of 2 mg ml1 prior to CE-MS analysis.
For the CE-MS analysis a Beckman Coulter P/ACE MDQ CE
system (Fullerton, USA) was used. Before analysis, samples were
centrifuged at 14 000  g for 10 min at 4 1C. The peptides
eluting from the CE were ionised using an electro-spray ionisa-
tion (Agilent Technologies, Palo Alto, CA, USA) which was
grounded to achieve electric potential of 0, and the electro-
spray interface potential of the microTOF mass spectrometer
(Bruker Daltonics, Bremen, Germany) was set between 4 and
4.5 kV. The mass calibration of the microTOF was performed
on a weekly basis using the standard protein/peptide solution
(0.5 pmol ml1) for CE-MS analysis. The acquisition of data and
MS were automatically controlled by the CE via contact close-
relays and MS spectra accumulated every 3 s, over a m/z range
350–3000 for 55 min.
MosaiquesVisu software was used to interpret the mass
spectral ion peaks representing identical molecules at diﬀerent
charge states and thus, those signals were deconvoluted into
single masses.34 The software automatically examined all mass
spectra from a CE-MS analysis for signals with a signal-to-
noise ratio of at least 4 present in three consecutive spectra.
Additionally, the isotopic distribution was assessed, and charge
was assigned on the basis of the isotopic distribution, as well as
conjugated masses, with a probabilistic clustering algorithm.
This operation resulted in a list wherein all signals that could
be interpreted are defined by mass/charge, charge, migration
time, and signal intensity (ion counts). Time-of-flight MS data
were calibrated with Fourier transform ion cyclotron resonance
MS data as reference masses applying linear regression.
CE migration time was calibrated by local regression with 488
reference signals or ‘‘housekeeping polypeptides’’. The obtained
peak lists characterize each polypeptide by its molecular mass
[Da], normalized CEmigration time [min] and normalized signal
intensity. All detected peptides were deposited, matched, and
annotated in a Microsoft SQL database allowing further statis-
tical analysis. For clustering, peptides in diﬀerent samples were
considered identical if mass deviation was o50 ppm. CE
migration time was controlled to be below 0.35 minutes after
calibration.
2.5 Peptides selection and statistical analysis
For the identification of potential IMI biomarkers, the normal-
ized levels of cow milk peptides were compared between time
point 0 h (non-infected or control group, n = 6) and time point
81 h (infected, n = 6). Only peptides that were detected with a
minimal frequency of 4 of 6 in at least one of the diagnostic
groups were considered for statistical analysis. Unadjusted P
values were calculated for the comparison between the non
infected and infected cow groups with the Wilcoxon rank-sum
test followed by adjustment for multiple testing with the
method described by Benjamini and Hochberg.35 Only peptides
with a corrected P o 0.05 were considered significant.
The number of peptides with diﬀerential abundance was
reduced to a support vector machine (SVM) classifier with
77 peptides (IMI77) by a take-one-out procedure. Sensitivity
and specificity of the biomarker classifier in the discovery set,
and 95% confidence intervals (95% IC) were calculated using
receiver operating characteristic (ROC) plots (MedCalc versio´n
14.8.1, MedCalc Software, Belgium).
2.6 Liquid chromatography and mass spectrometry for
peptide biomarker identification
In order to determine the sequences of significant biomarker
polypeptides, LC-MS/MS peptide sequencing was carried out as
previously described.11 Briefly, the milk extracts were analysed
on a Dionex Ultimate 3000 RSLS nano flow system (Dionex,
Camberly, UK). The samples were eluted with a gradient of
solvent A: 0.1% formic acid and acetonitrile (98 : 2) versus solvent
B: 0.1% formic acid and acetonitrile (20 : 80) starting at 5% B rising
to 50% B over 100 min. The column was washed using 90% B
before being equilibrated prior to the next sample being loaded.
The eluate from the column was directed to a Proxeon nano
spray ESI source (Thermo Fisher Hemel, UK) operating in
positive ion mode then into an Orbitrap Velos FTMS (Thermo
Fisher Hemel, UK). The ionisation voltage was 2.5 kV and the
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capillary temperature was 250 1C. The mass spectrometer was
operated in MS/MS mode scanning from 380 to 2000 amu.
Raw spectral data from LC-MS/MS analysis of the samples
were uploaded to Thermo Proteome Discoverer 1.3. Only pep-
tides with signal to noise ratio higher than 1.5 and belonging to
precursor peptides between 380–6000 Da were considered.
Peptide and protein identification was performed with the
SEQUEST algorithm. An in-house database containing proteins
from the latest version UniProt SwissProt database was com-
piled to include only Bos taurus and S. uberis entries. No enzyme
cleavage was selected and oxidation of methionine and proline
were chosen as variable modifications. Precursor mass tolerance
was set at 5 parts per million (ppm) and 0.1 Da for MS/MS
fragment ions. Resulting peptides and protein hits were further
screened by excluding peptides with an error tolerance higher
than 10 ppm and by accepting only those hits listed as high con-
fidence by Proteome Discoverer software. Target false discovery
rate (FDR) was 0.01 (strict) or 0.05 (relaxed).
3. Results
3.1 High abundance proteins
The alteration in the high abundance proteins of milk during the
experimental infection with S. uberis is shown in Fig. 1A with milk
protein from a single cow (cow 6) from 0 to 312 h PC separated by
SDS-PAGE. Similar gels for samples from all cows are given in ESI†
files (Fig. S1). The identity of the separated milk protein bands was
determined by MS analysis of bands cut from a reference gel of
healthy and mastitic milk (Fig. 1B) with the proteins identified
listed in Table 1. Similar patterns of change after infection of the
high abundance proteins of milk were obtained in samples of milk
from all the infected quarters, though with some variation in the
timing evident in Fig. S1 (ESI†). For instance the fall in the casein
proteins at Mw 28–31 kDa was apparent in all cows but was first
noticeable at 30 h (cow 2 & 3), 36 h (cow 1, 4, 6) or 42 h (cow 5) in
different cows. Although the identity of most proteins in Fig. 1A
and Fig. S1 (ESI†) was determined by comparison to the reference
gel (Table 1) the identity of the proteins at Mw 28–31 kDa was less
certain. The protein band at 31 kDa in healthy milk is as1-casein
and the protein at 28 kDa was b-casein, whereas in the mastitic
milk both of these bands were IgG light chain. The protein bands at
28–31 kDa appearing from 72 h PC could be either caseins or IgG
light chain. Overall the normal pattern ofmilk protein was found in
the initial samples with as1- and b caseins, b-lactoglobulin and
a-lactalbumin predominating. Thereafter, taking sample 6 as an
exemplar (Fig. 1A) these proteins are reduced between 30 and 81 h
PC while there is an increase in albumin, lactoferrin (LF) and IgG
heavy chain. Of these, an observable increase in albumin and IgG
took place at 36 h PC with LF having a more delayed response.
In comparing the albumin and LF protein bands, from 36–57 h
PC the albumin band was more intense while from 96–192 h PC
the LF band was more intense than the albumin (Fig. 1A).
In the last sample taken (312 h PC) all of the high abundance
proteins were still present, although infection had been resolved
in the majority of quarters.4
3.2 Acute phase proteins
The profiles of Hp, M-SAA3 and CRP over time during the
S. uberis mastitis challenge are shown in Fig. 2, 3 and 4 respec-
tively with the median value and the individual values shown for
the six infected quarters from cows 1, 2, 3, 4, 5, 6 (cow numbers
consistent with Tassi et al.4).
The earliest rise in Hp concentration was seen at 36 h PC
with concentrations over 100-fold the median for pre-challenge
(0 h PC) observed in 4 challenged quarters, and with all samples
reaching this level by 48 h PC. The maximum median concen-
tration of 421 mg ml1 (Fig. 2A) was observed at 72 h PC. At the
final time of sampling (312 h), two quarters still had elevated Hp
concentrations relative to basal values (cow 3 and 4 in Fig. 2B). In
control samples (n = 42), the range of Hp concentration was
o0.4–6.38 mg ml1, and in pre-challenge samples (0 h, n = 6) it
was o0.4–1.26 mg ml1.
The first rise in M-SAA3 levels was also observed at 36 h
PC with 5 of 6 milk samples showing at least a 20-fold increase
over the median of the 0 h PC samples and with all samples
showing more than a 100-fold the 0 h PC median by 48 h PC.
Fig. 1 (A) One dimensional gel showing high abundance proteins from a
mammary quarter challenged with Streptococcus uberis (panel A) (from
left to right: size marker with band size in kDa, 0, 6, 12, 18, 24, 30, 36, 42,
48, 57, 72, 81, 96, 120, 144, 68, 192, 240 and 312 hours post challenge).
Proteins were identified through comparison with results from reference
samples shown in (B) with the main proteins shown here: LF = lactoferrin;
Alb = albumin, Ig = Immunoglobulin; CN = casein; LG = lactoglobulin;
LA = lactalbumin. (B) One dimensional gel showing (left to right) high
abundance proteins from a healthy mammary quarter (a), high abundance
proteins from a quarter with clinical mastitis of unknown etiology (b), and
size marker with band sizes in kDa (c). Based on LC-MS/MS analysis
(Table 1), bands were identified as (1) IgG heavy chain and ceruloplasmin;
(2) lactoferrin, lactotransferrin precursor and serotransferrin precursor;
(3) albumin and complement C3; (4) Ig heavy chain precursor and IgG
heavy chain constant region; (5) Ig heavy chain precursor and light chain,
alpha-S1-casein; (6) immunoglobulin lambda like polypeptide and light chain;
(7) alpha-S1-casein and beta-lactoglobulin; (8) beta casein and component
PP3; (9) beta-lactoglobulin and alpha-S1-casein; (10) beta-lactoglobulin;
(11) alpha- and beta-lactoglobulin.
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Table 1 Milk proteins identified by LC-MS/MS after one dimensional SDS-PAGE separation of milk proteins
Band no. Proteins Protein ID Mass pI Mowse score Peptides Sequence cover (%)
1 IgG heavy chain gi|7547266 36 510 6.09 283 7 42
1 IgG heavy chain gi|91982959 36 562 6.49 210 6 36
1 Ceruloplasmin gi|296491101 121 901 5.68 90 9 9
2 Lactoferrin gi|408928 80 113 8.73 1896 40 61
2 Lactotransferrin precursor gi|30794292 80 002 8.69 1892 40 61
2 Serotransferrin precursor gi|114326282 79 856 6.75 403 21 33
3 Albumin gi|1351907 71 244 5.82 2449 47 68
3 Complement C3 isoform X1 gi|741932316 188 675 6.41 235 14 9
4 Ig heavy chain precursor gi|108750 51 391 6.1 215 6 19
4 IgG2a heavy chain constant region, partial gi|1699167 36 402 7.7 167 38 24
5 Ig heavy chain precursor gi|108750 51 391 6.1 251 7 23
5 Ig lambda light chain gi|15088675 25 032 5.84 132 4 20
5 Alpha-S1-casein isoform X2 gi|982928492 23 558 5.12 111 4 21
6 Ig lambda-like polypeptide 1 gi|741957421 25 010 8.19 457 10 44
6 Ig light chain, lambda gene cluster gi|92096965 24 863 7.53 449 9 37
7 Alpha-S1-casein gi|225632 24 477 4.85 665 8 40
7 Beta-lactoglobulin gi|2194088 18 583 4.83 115 6 32
8 Beta-casein isoform X1 gi|741930202 29 150 5.89 305 35 44
8 Component PP3 gi|741536 15 295 5.98 144 4 26
9 Beta-lactoglobulin gi|229460 18 641 4.76 163 6 48
9 Alpha-S1-casein isoform X13 gi|528953246 20 227 5.32 140 4 28
10 Beta-lactoglobulin gi|6980895 18 641 4.76 2325 18 82
11 Alpha-lactalbumin gi|68 14 603 4.8 392 4 39
11 Beta-lactoglobulin gi|2194088 18 583 4.83 308 8 48
Fig. 2 Haptoglobin concentration in bovine mammary quarters challenged with Streptococcus uberis (infected, n = 6) or mock challenged with
phosphate buﬀered saline (controls, n = 6). Results show median (A) and individual (B) concentrations.
Fig. 3 Mammary associated SAA3 concentration in bovine mammary quarters challenged with Streptococcus uberis (infected, n = 6) or mock
challenged with phosphate buﬀered saline (controls, n = 6). Results show median (A) and individual (B) concentrations.
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The maximummedian concentration of M-SAA3 was at 96 h was
9900 mg ml1 (Fig. 3A). At 312 h, two quarters had high M-SAA3
concentration; these two quarters were the same ones which had
higher Hp concentration at 312 h (cow 3 and 4, Fig. 3B). A range
of o0.6–18.68 mg ml1 was found in control samples and
o0.6–19.22 mg ml1 in pre-challenge samples (0 h).
For CRP, the first rise in concentration in milk was at 30 h PC
with 3 of 6 samples at least 300 the 0 h PCmedian concentration
and with all samples having over 1000 the value at 48 h PC.
Peak median concentrations of CRP were achieved at 72 h at
16 687 ng ml1 (Fig. 4A). At 120 h PC there was a peak of CRP in
cow 3 at 102000 ngml1 while at 240 h CRP concentrations in cows
2 and 3 were noticeably higher than in the other cows (Fig. 4B). The
range of CRP in control samples waso1.8–41.44 ng ml1 and was
o1.8 ng ml1 in pre-challenge samples.
3.3 IMI77 classifier based on CE-MS datasets
In order to detect IMI in cows, CE-MS datasets from 6 cows
were analysed. According to specific guidelines on biomarker
studies,36 samples were split into the discovery cohort formed
by 12 samples, 6 samples from 0 h PC (non infected, NI) and
6 infected cows from 81 h PC (infected, I). The validation cohort
consisted of 23 milk samples collected at 36, 42, 57 and 312 h
PC (for all time points n = 6, except for 36 h PC where n = 5 as
there was insuﬃcient volume for one sample).
Comparison of the peptide profiles from the two sets of
samples in the discovery cohort led to the identification of 460
peptides with adjusted BH p-value significant (P o 0.05) that
were present in at least 66% of the control or diseased groups.
Those displaying an AUC = 1 were further considered for the
study (205 peptides). LC-MS/MS analysis, and data matching
with those from Mansor et al.11 allowed 77 sequences to be
obtained from these 205 peptides (Table 2). Peptide maps
(CE-MS peaks) of potential biomarkers of S. uberis mastitis
which were up-regulated or down regulated during infection at
36, 42, 57 and 81 h PC relative to 0 h (pre-challenge) are shown
in Fig. 5. Out of the 77 peptides, 50 showed qualitative
diﬀerences between the 0 and 81 h PC (being totally absent at
one time as against the other), and 27 displayed quantitative
changes with the course of infection. Fifty-five polypeptides
were increased in abundance. Among them, the most abundant
fragments corresponded to proteins such as alpha-S1-casein and
alpha-S2-casein (36 peptides), beta-casein (22 peptides), serum
amyloid and Glycosylation-dependent cell adhesion molecule 1
(GDCAM) (5 peptides each). The 77 sequence peptides were then
used in a support vector machine (SVM) classifier called IMI77.
After applying cross-validation of the discovery data, no peptide
was left out from the final classifier. Scoring the animals from
the discovery cohort with the resulting IMI77 classifier clearly
separated non infected cows from the infected ones. In the next
step, the classifier was applied to the 23 samples that were not
used in the discovery cohort to see its performance in the
progression of IMI. The distribution of IMI77 scores for the dis-
covery and validation cohort showed a pattern where the score
increased with the time of infection up to 81 h PC but with
samples from 312 h PC the score was more comparable to
control than infected animals (Fig. 6).
3.4 Liquid chromatography and mass spectrometry
Liquid chromatography-tandem mass spectrometry allowed for
sequencing of the 77 peptides in the biomarker panel which
were matched with 3 multi-consensus reports and a report of
Mansor et al.11 Along with some of their characteristics, they
are listed in Table 2. Mass to charge ratio (m/z) range of the
sequenced peptides was from 498.93 to 1008.88 Da and mass
range from 1016.5 to 3610.74 Da. Most of the sequenced
peptides arose from cleavages of alpha-S1-casein and other
caseins. A few were from SAA and GDCAM proteins. Some of
the peptides derived from SAA protein were up regulated by
several thousand folds during peak of infection, for example;
GADKYFHARGNYDAA, GADKYFHARGNYDAAQRGPGGAWAA
and SGKDPNHFRPAGLPDKY.
The greatest fold change (12 223) occurred with the poly-
peptide GWRLPEYTVTQESGPAHRKEFTMTCRVERF which had
sequences matching into the RISC-loading complex subunit
protein. This peptide was themost up regulated peptide identified
followed by SGKDPNHFRPAGLPDKY derived from SAA protein
(10 457). There were 22 peptides which were down regulated
among the total 77 sequenced and these were derived mainly
from alpha-caseins and GDCAM proteins.
Fig. 4 C-Reactive protein concentration in bovine mammary quarters challenged with Streptococcus uberis (infected, n = 6) or mock challenged with
phosphate buﬀered saline (controls, n = 6). Results show median (A) and individual (B) concentrations.
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4. Discussion
In order to integrate the results on the high abundance proteins,
the APP and peptides in milk in relation to changes already
described by Tassi et al.,4 Fig. 7 shows the change in selected
analyte levels from the current and the previous studies based on
the percentage of the maximal increase for each. To further
enable interpretation and integration of data Fig. 8 shows the
mean bacterial count and rectal temperatures of the infected
cows as previously described.4 Bacterial count in milk was the
first parameter to increase being observed at 12 h PC, reaching a
peak at 36 h PC and falling to around 50% of peak bacteria from
72 h PC to the end of study. It should be noted that IMI would
normally be defined based on the presence of bacteria in milk
samples, whereby three consecutive negative samples are needed
to declare an animal free of IMI. The SCC first increased at
30 h PC, reached a peak at 48 h PC and plateaued at this level
virtually to the end of the study. Among the cytokines, IL1b,
TNFa and IL6 reached peaks between 36–72 h PC and declined
to low levels by 120 h PC.
4.1 High abundance proteins of milk
The IMI with S. uberis caused significant change in the high
abundance milk proteins and increases in milk APP. While there
was between animal variations in the response of high abundance
proteins to IMI, there were consistent changes seen along the time
course of the infection in the sets of milk samples from each
infected udder quarter. The decrease in caseins, b-lactoglobulin
and a-lactalbumin and increase in albumin, LF and IgG following
infection of the mammary are well known18,19,29 but here the
timing of the responses has been identified. With cow 6 (Fig. 1) as
an example the fall in caseins of 28–38 kDa was seen first at 36 h
PC, occurring after bacterial count and SCC increases which were
at 12 h and 30 h PC respectively but at the same time as increases
in cytokines such as TNFa and IL1b.4 There was a subsequent
increase in the protein at 28–38 kDa from 72 h PC but in
mastitic milk (Fig. 1B) Ig light chain has a similar mobility and
with one dimensional electrophoresis it is not possible to
differentiate between these proteins. Two dimensional electro-
phoresis or immunoassay would be needed to achieve this
purpose. Increases in albumin and IgG occurred later, at 81 h
PC, while the peak of LF was further delayed to 120 h PC. Thus
changes in the concentrations of high abundance proteins of
milk following IMI are not uniform across proteins. It may be
that, by monitoring relative concentrations of these proteins,
alone or as part of a diagnostic panel, the stage of infection
Fig. 7 The relative responses of analytes following experimental infections with S. uberis combining results from this investigation and those described
by Tassi et al.4 The shading represents increasing responses in relation to the peak response and represents 25%, 50%, 75% and 100% of peak response on
days PC. Responses were increased from the day 0 levels except where indicated by * which were decreases with respect to the day 0 level.
Fig. 5 Peptides detected in milk fluid and diﬀerences between non-
infected cows (0 h PC) and infected (36, 42, 57 and 81 h PC). Representation
of the up-regulated (left panel) and down-regulated (right panel) peptides
analysed by CE-MS. Each peptide was identified by a unique identifier based
on the migration time (min) and specific mass (kDa), with a peak height
representing the relative abundance.
Fig. 6 Performance of the classifier in the discovery cohort (0 and 81 hours)
and progression of infection (36 h, 42 h, 57 h, 312 h PC). Box whisker
plot according to the IMI77 score showing median, 10th, 25th, 75th and
90th percentiles.
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could be identified. Although IMI had been resolved in 5 of
6 animals by 312 h PC,3 the composition of high abundance
proteins had not reverted to pre-challenge levels. By contrast,
SCC levels were still high in all cows at 312 PC,4 implying that
host rather than bacterial proteases are responsible for protein
degradation.
4.2 Acute phase proteins
For the APP, the time course of increase in Hp and M-SAA3 have
been described in response to S. aureus mastitis10 but the
changes in milk CRP during any experimental model of mastitis
have not previously been demonstrated. In respect to the cytokine
response the maximum of Hp, M-SAA3 and CRP concentration
were after the peak cytokine responses (Fig. 7).
There was variation between the individual cows in APP
response, as there had been in clinical and bacteriological
response.4 Milk Hp was first increased from basal values at
36 h PC in 4 cows with the median Hp across all cows peaking
at 72 h PC. Notably, over several hundred fold increase in milk
Hp concentration was observed at the peak, highlighting the
strong response of milk Hp to the IMI. Elevation of milk CRP
was the earliest to occur with the initial increase being observed
at 30 h pi in 3 out of the six cows while M-SAA3 was the last to
be raised with only a 20 increase seen at 36 h PC. There were
diﬀerences between animals as well as between the APP, but
the APP responses were consistent in a number of aspects. At
least 24 h passed between infection and any elevation of the
milk APP concentration. The APP showed over a thousand fold
increase in their concentrations with maximum median con-
centrations at 72–96 h PC, thereafter falling though in some
cows the basal level of the APP had not been reached by 312 h
PC. The fall in APP after 72 h PC occurred even though the SCC
remained elevated for the duration of the 312 h of the study and
in the resolution phase more closely resembled the profile of
bacterial counts in the milk than the SCC. Hence, APP may be a
better biomarker of IMI than SCC.
There are diﬀerences to previous reports on APP in mastitis.
Pedersen and others (2003)23 and Jacobsen et al. (2005)37 demon-
strated an earlier rise in M-SAA3 than Hp during the course of an
S. uberis intramammary challenge. The diﬀerence in comparison
to our results could be due to strain diﬀerences in the S. uberis
used for challenge leading to diﬀerent cytokine activation
pathways16 and could also be influenced by a diﬀerence in
host genotype or phenotype. While assays for bovine CRP have
only recently become available it could be that using such an
analyte with a lower detection limit and a large dynamic range
will accentuate the value of this APP in detecting mastitis.
Previously, although CRP had been identified as a milk APP24
it has not generally been regarded as a bovine APP for use as a
biomarker of mastitis, but availability of the immunoassay
used here for bovine CRP will allow its diagnostic value to be
assessed at a larger scale. Currently, of the three APP, Hp is the
easiest to measure with availability of specific antibody for the
development of varied immunoassay formats and a large response
even if its peak response is later than that of CRP. The stage of IMI
and the species of pathogen are known to cause diﬀering mam-
mary responses.38,39 While attempts to diﬀerentiate pathogen and
stage of IMI by APP analysis have yielded disappointing results40
an aim of the current series of studies is to determine whether
diﬀerentiation is possible with inclusion not only of Hp, MSAA3
and CRP but also change in the high abundance proteins,
peptides and metabolites possibly yielding a diagnostic algorithm
similar to those being developed for protein profiles being devel-
oped in clinical proteomics41 and could yield diagnostic value for
mastitis detection and monitoring.
4.3 Peptidomics
A limitation of previous investigations of the responses of milk
proteins to mastitis has been that, due to the lack of suitable
methods, the low Mw proteins and peptides in milk are fre-
quently ignored. Recently the use of methods specific for pep-
tides of o25 kDa have suggested that there are major changes
in these molecules in mastitis. CE-MS analysis of bovine milk
during natural mastitis11 detected peptide diﬀerences between
milk samples from control and naturally infected udders
(31 polypeptides) and between milk frommastitic udders caused
by two separate pathogens (14 polypeptides). This method of
peptide analysis has been described as a powerful hyphenated
Fig. 8 Course of infection in challenged cows (n = 6) as indicated by average body temperature and average bacterial count in milk. Number of culture
positive quarters ranged from six at 18 to 72, 105 and 129 h post challenge to one at 312 h post challenge.4 Vertical lines indicate time points for which
peptidomic analysis was conducted. Normally IMI definition is based on the presence of bacteria in milk samples, whereby three consecutive negative
samples are needed to declare an animal free of IMI.
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technique for the study of peptidomic profiles42 and has been
exploited for the generation of biomarker panel of peptides for
conditions such as renal43 and cardiovascular44 disorders in
humans.
A majority of the successfully sequenced changing peptides
from this challenge study arose from cleavages of alpha-S1-
casein (n = 31) and beta-casein (22 milk proteins), in agreement
with the reports of Dallas et al. (2014),45 Mansor et al. (2013)11
and Larsen et al. (2010)46 and despite diﬀerences in causative
agents between studies. This further explains the general decrease
in milk caseins associated with clinical mastitis20 and shown here
in Fig. 1. It has been postulated that S. uberis is dependent on
casein cleavage to obtain nutrients during IMI,47 but shifts in
protein and peptide distributions persist beyond resolution of
infection so casein cleavage is not dependent on the pathogen.
A few of the peptides showing change were not from casein
degradation but from GDCAM, (mainly down regulated), and
SAA (up regulated) cleavages. These two proteins have been
identified as immune related proteins.29,48,49 Presence of GDCAM
could relate to the role proposed for host glycosaminoglycans in
the pathogenesis of S. uberismastitis.50,51 Proteases play a central
role in the type and amounts of peptides detected in milk during
mastitis and endogenous peptides such as plasmin, cathepsins,
elastase, and amino- and carboxypeptidases have been suggested
as being crucial during the IMI as they are increased in milk
due to release from the influx of neutrophils (PMNs) and other
phagocytic cells, measured as the SCC, that occurs during
mastitis.46,52 These proteases were also reported to have speci-
ficities towards alpha-S1 and beta caseins. Pathogen related
proteases have also been suggested to contribute to the proteo-
lysis observed in milk during mastitis.46
Similar to the study of Wedholm et al. (2008),53 peptides
from alpha-S1, alpha-S2 and beta-caseins were identified but
in addition two kappa-caseins fragments were found and
sequenced during infection but were absent in pre-challenge
samples. This corresponds to the eﬀect of LPS infusion in an
experimental mastitis model generating proteolytic changes of
milk over time.52
Three polypeptides sequenced in this study were similarly
identified in both the multi-consensus andMansor et al. (2013)11
reports. Two of these peptides were fragments from GlyCAM-1
protein and one was from cleavage of fibroblast growth factor-
binding protein (FGFBP). All of these three polypeptides were
found in pre-challenge samples and absent during infection,
while in the study of Mansor et al. (2013),11 these polypeptides
only diﬀerentiated between healthy and mastitic samples and
not between the two diﬀerent mastitis pathogen species studied
(i.e. E. coli and S. aureus). The matching of these peptides from
the present study, the study of Mansor et al. (2013)11 and with
reports from previous CE-MS milk analysis substantiates their
probability as peptide markers of mastitis irrespective of the
causal agent of mastitis.
As a time-point-based peptidomic study of mastitis progres-
sion, this study oﬀers additional advantage over other previous
investigations in detecting and identifying peptides and in
showing significant diﬀerence from pre-challenge controls,
as early as 36 h PC. The probability exists that the peptidomic
profile at earlier time points (before 36 h) may significantly
diﬀerentiate pre-challenge samples from commencement of
infection but were not analysed here due to resource limita-
tions. As an objective for future studies, it would be useful to
determine the earliest time point during which peptide changes
are able to significantly diﬀerentiate healthy from infected
samples to provide an early warning of impending mastitis.
The increase in IMI77 classification score up to 81 h PC shows
that peptide proteolysis increases while the bacterial count
declined after 30 h PC. The proteolytic activity may thus be more
likely to be emanating from endogenous proteases rather than
those of bacterial origin. It was of interest that at 81 h PC there
were no peptides derived from albumin, lactoferrin or IgG despite
these being the most abundant proteins in the milk at this time
point. These proteins may be more resistant to degradation by
the proteases present in the milk than the caseins. This could be
a part of an anti-bacterial function of the alteration of the milk
proteome in mastitis by depriving bacteria of protein as a
nutrient but still providing protein in the milk that would be
digested by the neonate’s gastro-intestinal tract.
In respect of a peptide panel that could diﬀerentiate mastitis
caused by S. uberis from other pathogens, 72 of the polypeptides
which were sequenced in this study, did not match any of the
polypeptides detected in Mansor et al.’s study11 of S. aureus and
E. coli mastitis or any of the multi-consensus reports. Therefore,
these 72 peptides could represent a panel of peptides specific to
S. uberis mastitis. Validation of this claim would be required
using other S. uberis mastitis models such as natural infection
and infections by diﬀerent strains of S. uberis.
The time points that were selected for peptidomic analysis
were based on the clinical and bacteriological course of infection,
whereby the peak of infection seemed to have ended by 81 h post
challenge (Fig. 8). Surprisingly, the biggest peptidomic diﬀerence
between pre-challenge and post-challenge samples was detected
in the validation set, using samples from 81 h post challenges.
Indeed, changes in high abundance proteins, APP and peptido-
mic profiles all persisted beyond the clinical and bacteriological
peak of IMI, indicating that bacteriological, clinical and pepti-
domic events are partly out of synch. This is consistent with the
idea that changes in proteins and peptides are largely driven by
the host immune response and SCC influx rather than directly by
bacteria. At the last observed time point, 312 h PC, the IMI77
classifier scores were still significantly diﬀerent from the pre-
challenge time point, but much closer to pre-challenge values
than for any other time point considered in this study. At 312 h
PC, 5 of 6 cows had resolved the IMI and all cows and quarters
appeared clinically normal.3 Thus, the change in IMI77 score
reflects the natural resolution of IMI. It would be interesting to
explore the relationship between bacteriological status and pep-
tide profile at individual cow level for multiple time points during
the IMI resolution phase but samples to do so were not available
from the current study.
Early detection and diﬀerential diagnosis of the mastitis
causing pathogen would be valuable for the dairy industry, for
earlier and more eﬀective treatment and also to reduce the use
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of ineﬀectual antimicrobials which would lead to a reduction in
resistance to these therapeutics. On large dairy farms operating
under high economic pressure and on farms with automated
milking systems, clinical symptoms would not be noticed because
regular observation of individual animals does not take place.
Under those circumstances, alternative diagnostic indicators are
potentially of great value. It is clear that both APP and peptide
analysis could play a role in this scenario and when combined with
quantitative proteomics12 and metabolomics,13 that integration of
protein assay and omic technologies has major potential for
delivering a unified and substantial means to provide a molecular
insight into a complex biological system and to stimulate bio-
marker development across omic boundaries.
5. Conclusion
The high abundance protein and APP profiles of milk during an
experimental S. uberis mastitis challenge were investigated, with a
shift in abundance from caseins, b-lactoglobulin and a-lactalbumin
to albumin, lactoferrin and IgG being observed following infection.
The APP profiles of Hp, M-SAA3 and CRP were closer to the
bacterial count than the SCC in milk from infected quarters and
may have value in diagnosing and monitoring the stage of IMI.
Analysis of the peptide profile inmilk across selected time points of
the experimental challenge, showed a panel of peptides, which as
early as 36 h PC, could significantly diﬀerentiate infected from non-
infected milk, thus suggesting potential as biomarkers of bovine
mastitis. Moreover, the identification of peptidomic markers that
were not detected in clinical mastitis due to other pathogens
suggests that pathogen specific diagnosis is possible.
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